On Tuesday, SurModics Inc. (SRDX) announced that it licensed its drug delivery technology to Roche (RHHBY) and its wholly owned subsidiary, Genentech. Drug delivery technologies create and support site specific drug delivery polymers and coating technologies for use in drug/device combination products in chosen markets.    Under the terms of the agreement, SurModics is entitled to an up-front payment of $3.5 million. Furthermore, the deal could be worth up to $200 million in delayed payments if multiple products are successfully developed. SurModics will also receive royalties on product sales. SurModics will receive payments for its development services. Under the terms of the agreement, Roche and Genentech have the right to obtain manufacturing services from SurModics.   The transaction provides Roche and Genentech complete access to the biodegradable microparticles developed by SurModics. They intend to use the products in a long-lasting version of their optical drug Lucentis ...

Early Thursday morning, OxiGENE Inc came up with an announcement that its Chief Executive Officer, John A. Kollins has resigned from his position with the Company and also as a member of the Board of Directors in order to pursue other interests. Soon after the news was out in the market, shares of OxiGENE dropped but later on it bounced back to $1.36 in the afternoon trading. OxiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cancer and eye diseases. The company mainly focuses on the development of vascular disrupting agents (VDA) that selectively disrupts abnormal blood vessels associated with solid tumor progression and visual impairment.

In the absence of the top leading position, Dr. Peter Langecker who is currently the Vice President and Chief Development Officer

...

Companies featured in this edition of the newsletter: ACTC, CHIP, CUR, CVM, ENZ, IMUC, IWEB, SRCO, SVUL, XSNX

Markets finally snapped their winning streak last week, as weakness in housing markets and durable goods orders led to broad-based declines in all of the major indices. All told, the Dow surrendered 155 points on the week to close at 9665, down 1.6% on the week but up 10.1% on the year. The Nasdaq lost 2.0% on the week to close at 2090, up 32.6% on the year, while the S&P 500 and Russell 2000 posted losses of 2.2% and 3.1% respectively, paring their yearly gains to 15.6% and 19.9%.

Unexpectedly poor data from the housing sector was the big economic story on the week as both new and existing August home sales failed to live up to expectations. New home sales increased modestly to 429,000, falling short of estimates calling

...

For Immediate Release

Chicago, IL – September 18, 2009 – Zacks Equity Research highlights ON Semiconductor (ONNN) as the Bull of the Day and Developers Diversified (DDR) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Alcon Inc.(ACL), AstraZeneca (AZN) and Allergan, Inc.(AGN).

Full analysis of all these stocks is available at http://at.zacks.com/?id=2676

Here is a synopsis of all five stocks:

Bull of the Day:

ON Semiconductor (ONNN) is an OEM of primarily analog semiconductors used within a diverse set of end markets. June quarter results beat consensus expectations, with management guiding for stronger results in the September quarter.

Recent acquisitions, a broad product portfolio, a well diversified business across end markets and geographies, restructuring actions and debt reduction initiatives are other positive factors.

While competition is strong as ever and restrictive covenants and some residual integration

...

DrStockPick.com Stock Report!

Friday July 24, 2009

**************************************************************

OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report second quarter 2009 results on Thursday, July 30, 2009. A conference call and webcast hosted by OXiGENE management will begin at 10:00 a.m. EDT (7:00 a.m. PDT).

LPP, the largest clothing retailer in Central and Eastern Europe, met 31 pre-screened Greater China suppliers at Global Sources’ (Nasdaq: GSOL) Custom Private Sourcing Event ( http://www.PrivateSourcingEvents.com ) in Shanghai on July 16, 2009.

Chemspec International Limited (NYSE: CPC), a leading China-based contract manufacturer of highly-engineered specialty chemicals, today announced two recent senior management appointments: Dr. Jinhua (Jim) Chen was promoted to the vice president of process research and development,

...

We often take our eyesight for granted until it’s too late. More than 1.7 million people over the age of 65 are afflicted with age-related macular degeneration, taking away the precious gift of sight. The loss of function in retinal cells can lead to impairment or total loss of vision. While scientific advances to treat diseases of the eye are constantly being made, approximately 65,000 people in the United States are affected by the most common types of retinitis pigmentosa.

As its name implies, StemCells Inc. (Nasdaq: STEM) concentrates on the discovery, development and commercialization of cell-based therapeutics to treat diseases affecting the central nervous system and liver. The company today announced that its HuCNS-SC product candidate, when transplanted into a well-established animal model, can protect the retina from progressive degeneration, which can lead to the loss of vision in age-related eye diseases.

The study was conducted by Dr.

...

IRIDEX Corporation (NASDAQ: IRIX), a worldwide leader in the development, manufacturing, and marketing innovative and versatile light-based medical systems and delivery devices, recently announced receipt of FDA 510(k) clearance for its suite of IRIDEX IQ Laser Systems, covering the IRIDEX IQ 532, IQ 577, IQ 630-670 and IQ 810 Laser Systems along with their associated delivery devices. The company developed these laser systems to assist with a wide range of specific applications in the medical specialties of ophthalmology, ear, nose and throat (ENT)/otolaryngology and dermatology.

The company’s president and chief operating officer, Mr. Theodore A. Boutacoff, recently stated, “We are pleased to have passed this regulatory milestone. The design concept of the IQ Family enables us to provide different solid-state lasers on a common platform. The first product to be released to market using this platform will be the IQ 577™, which provides a wavelength and technology that complements our product

...

Alcon Inc. is a Switzerland developer of pharmaceuticals, surgical tools, contact lens care, and other products for eye diseases and disorders. On April 23rd it raised its expectations for 2008 earnings to $6.39-$6.49 per share on revenue of $6.4 to $6.5 billion, above previous guidance.

This continues a very bullish trend of strong earnings for this medical company that is standing out as the leader in a group that is slowly starting to rise as CYBX, ABMD, EXAC, NUVA, and EW all have the same chart patterns the past six months. As this group comes into favor though, this company stands out based on the fundamentals.

EPS has grown 17%, 16%, 40%, 27%, 25%, 31%, 13%, and 18% the past eight quarters. Along with that stunning growth for a big stock, sales are just as impressive with growth of 12%, 12%, 16%, 14%, 12%, 11%, 20%, and 16% the past eight quarters. …